ERBB2 and breast carcinoma: In CLEOPATRA, a phase-III trial of pertuzumab in combination with trastuzumab and docetaxel in patients with HER2+ advanced breast cancer, the overall incidence of adverse events was higher in Asian vs non-Asian patients [17].